ArticlebioRxiv : the preprint server for biology2024

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity.

Xin Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.